Iovance Biotherapeutics, Inc. vs Galapagos NV: SG&A Expense Trends

SG&A Expense Trends: A Tale of Two Biotech Giants

In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech companies: Iovance Biotherapeutics, Inc. and Galapagos NV, from 2014 to 2023.

A Decade of Financial Evolution

Over the past decade, Galapagos NV has seen a staggering increase in SG&A expenses, peaking in 2022 with a 2,500% rise from 2014. Meanwhile, Iovance Biotherapeutics, Inc. has also experienced significant growth, with expenses increasing by over 1,000% during the same period. Notably, in 2023, Iovance's SG&A expenses surpassed Galapagos, marking a pivotal shift in financial strategy.

Strategic Implications

These trends reflect strategic investments in marketing, administration, and sales, crucial for sustaining growth in the competitive biotech landscape. Investors should consider these financial trajectories when evaluating the long-term potential of these companies.